COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More
Clinical Trials Search
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
Primary- To determine the objective response rate by independent radiologic review to single agent seribantumab (anti-HER3 targeted therapy) in patients with centrally confirmed NRG1 gene fusion positive advanced cancer according to RECIST 1.1.